Galena Biopharma Inc news

   Watch this stock
Showing stories 1 - 10 of about 94   

Articles published

GALE 1.55 +0.13 (9.15%)
price chart
Company Update (NASDAQ:GALE): Galena Biopharma Inc Announces ...
Galena Biopharma Inc (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, announced two abstract ...
Galena Biopharma Announces Publication of Two Abstracts at the 2015 ...  GlobeNewswire (press release)
Galena Biopharma Inc. (GALE) is Trading Higher on Unusual Volume for May 26  Equities.com
Active Stocks in Focus: Galena Biopharma Inc (NASDAQ:GALE), Booz Allen ...
Galena Biopharma, stated its financial results for the quarter ended March 31, 2015 and offered a business update. “We achieved two critical milestones thus far this year with completion of enrollment in our Phase 3 PRESENT trial and the closing of a ...
Galena Biopharma, Inc. Analyst Rating Update  News Watch International
Active Biotech Stock News - Galena Biopharma (NASDAQ:GALE), Alexion ...  Wall Street Observer
Why Galena Biopharma, Inc. Stock Crashed By 52% in 2014
The overall market may be on pace to deliver solid gains for investors in 2014, but shareholders in Galena Biopharma (NASDAQ: GALE ) can do nothing but shake their head in disappointment with their stock down 52% for the year.
Related articles »  
Company Update (NASDAQ:GALE): Galena Biopharma Inc to Present GALE ...
Galena Biopharma Inc (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, announced that data from the ...
Galena Biopharma to Present GALE-401 (Anagrelide Controlled Release ...  MarketWatch
Galena Biopharma Inc. Imploded in March -- Here's Why
What: Shares of Galena Biopharma (NASDAQ: GALE ) , a predominantly clinical-stage biopharmaceutical specialist focused on developing novel cancer vaccines, sank 23% in March (according to data from S&P Capital IQ) after the company reported ...
Galena stock tanks as biotech darling records slow sales of new drug  Portland Business Journal (blog)
Stock Update (NASDAQ:GALE): Galena Biopharma Inc Reports First Quarter ...
Galena Biopharma Inc (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today reported its financial results ...
Galena Biopharma Reports First Quarter 2015 Financial Results  CNNMoney
Galena Biopharma (GALE) Set to Announce Earnings on Thursday  Dakota Financial News
MLV Reiterates Buy on Galena Biopharma Inc Following Enrollment Expansion ...
MLV's healthcare analyst Vernon Bernardino came out with a few insights on Galena Biopharma Inc (NASDAQ:GALE), after the company announced expansion of targeted patient population for its ongoing Phase 2b clinical trial with NeuVax in combination ...
Cantor Remains Cautious on Galena Biopharma Inc Following 4Q Earnings
In a research report issued today, Cantor analyst Mara Goldstein maintained a Sell rating on Galena Biopharma Inc (NASDAQ:GALE) with a $2.00 price target, following the company's fourth-quarter results, posting earnings of ($0.06) per share on revenues ...
Galena Biopharma Reports Fourth Quarter and Year End 2014 Financial Results  GlobeNewswire (press release)
Galena Biopharma's (GALE) CEO Mark Schwartz on Q4 2014 Results ...  Seeking Alpha (registration)
Galena Biopharma Inc (GALE) Releases Q4 Report Amid SEC Investigation
Aside from Galena Biopharma's earnings report, the company is currently under investigation by the SEC regarding a shareholder derivative suit.
Galena Biopharma (GALE) Falls: Stock Goes Down 6%  Zacks.com
Galena Biopharma Receives Buy Rating from Noble Financial (GALE)  Dakota Financial News
MLV Pounds the Table on Galena Biopharma Inc
MLV analyst Vernon Bernardino was out pounding the table on Galena Biopharma Inc (NASDAQ:GALE) Monday, reiterating a Buy rating and a $5 price target, which implies an upside of 236% from current levels.
MLV & Co Analysts Give Galena Biopharma a $5.00 Price Target (GALE)  Dakota Financial News